<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Primary cytoreductive surgery (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e>) and peri-operative intraperitoneal chemotherapy (PIC) is the only curative option for patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> <z:e sem="disease" ids="C1332128" disease_type="Neoplastic Process" abbrv="">peritoneal carcinomatosis</z:e> (PC) </plain></SENT>
<SENT sid="1" pm="."><plain>A significant proportion of patients develop peritoneal recurrence </plain></SENT>
<SENT sid="2" pm="."><plain>Outcomes of patients undergoing secondary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e> and PIC for recurrent PC were examined </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: <z:hpo ids='HP_0000001'>All</z:hpo> patients undergoing second procedures with curative intent for recurrent appendiceal or <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> PC in three centers were included </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with recurrent <z:mpath ids='MPATH_303'>pseudomyxoma peritonei</z:mpath> (<z:chebi fb="5" ids="38786">PMP</z:chebi>) were excluded </plain></SENT>
<SENT sid="5" pm="."><plain>Morbidity and mortality, overall survival, and disease-free survival were primary outcome parameters </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The study included 18 patients (13 colorectal and 5 appendiceal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>) </plain></SENT>
<SENT sid="7" pm="."><plain>At primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e>, mean <z:e sem="disease" ids="C0153467" disease_type="Neoplastic Process" abbrv="">Peritoneal Cancer</z:e> Index (PCI) was 9.1 </plain></SENT>
<SENT sid="8" pm="."><plain>In 13 patients complete resection was achieved </plain></SENT>
<SENT sid="9" pm="."><plain>Median time to recurrence was 14 months (range: 1-33) </plain></SENT>
<SENT sid="10" pm="."><plain>At secondary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e>, mean PCI was 6.3 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e> was complete in 13 patients </plain></SENT>
<SENT sid="11" pm="."><plain>There was no 30-day mortality and 1- and 2-year survival were 74% and 50%, respectively </plain></SENT>
<SENT sid="12" pm="."><plain>In 14 patients a recurrence after the second procedure was diagnosed </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: A secondary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e> for recurrent colorectal or <z:e sem="disease" ids="C0496779" disease_type="Neoplastic Process" abbrv="">appendiceal cancer</z:e> PC is safe and feasible, however, relapse is frequent </plain></SENT>
<SENT sid="14" pm="."><plain>Further investigations are required to critically assess the efficacy of a secondary procedure and to define optimal patient selection criteria in the era of effective modern chemotherapy </plain></SENT>
<SENT sid="15" pm="."><plain>J </plain></SENT>
<SENT sid="16" pm="."><plain>Surg </plain></SENT>
<SENT sid="17" pm="."><plain>Oncol Â© 2012 Wiley Periodicals, Inc </plain></SENT>
</text></document>